SMS Pharmaceuticals logo

SMS Pharmaceuticals financials and balance sheet

NSE: SMSPHARMABSE: 532815Pharmaceuticals & BiotechnologySmall Cap

Last close ₹414.60down ₹14.05 (3.28%)BSE ₹414.70

Share price at the NSE close on 23 Oct 2026. Previous close ₹428.65.

52-week range of traded prices to 23 Oct 2026
₹270.10Low, 24 Nov 2025₹494.45High, 22 Sep 2026
Market cap
₹3,883 Cr920th largest listed
P/E
37.8
P/B
4.9
Dividend yield
0.10%
ROE
14.4%
ROCE
11.5%
Debt to equity
0.46
Volume, NSE
4,58,39343.4% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.SMS Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹887 Cr, year to Mar 2026A loss in 1 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.3% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue887
  2. Materials and goods−493
  3. Employee costs−88
  4. Other expenses−134
  5. Operating profit171
  6. Depreciation−40
  7. Other income+8.4
  8. One-off items0.0
  9. Finance costs−23
  10. Profit before tax117
  11. Tax−29
  12. Joint ventures+14
  13. Net profit102

What the company owns

  • Plant, investments and other assets₹749 Cr
  • Inventory₹351 Cr
  • Receivables₹216 Cr
  • Cash and bank₹46 Cr

What pays for it: net worth and liabilities

  • Net worth₹786 Cr
  • Borrowings₹365 Cr
  • Owed to suppliers₹120 Cr
  • Other liabilities₹91 Cr

Profit and loss

Consolidated, ₹ crore, years to March.SMS Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 6 JunMar 2021Mar 2022Filed 13 JunMar 2023Filed 24 MayMar 2024Filed 19 JulMar 2025Filed 13 JunMar 2026Filed 22 May
Revenue from operations654465465412563520522709783887
551372375332442406468593644716
Materials and goods bought416290293246340275336424437493
Employee costs44–3639–5155648088
Other expenses91–4746–7977104127134
Operating profit before depreciation10393908012111455117139171
Operating margin15.7%20.1%19.4%19.4%21.5%22.0%10.4%16.4%17.8%19.3%
Materials, % of revenue63.6%–63.0%59.8%–53.0%64.3%59.8%55.8%55.6%
Employee costs, % of revenue6.8%–7.7%9.6%–9.8%10.5%9.0%10.2%9.9%
Other expenses, % of revenue13.9%–10.0%11.2%–15.2%14.7%14.7%16.2%15.1%
Depreciation and amortisation25201922223232323440
Operating profit after depreciation7873715899822285105131
Other income3235355468
Finance costs21151212111922231923
One-off items0000000000
Profit before tax60606251916856692117
12209183011172529
Share of profit of joint ventures and associates−7–––2−6−111214
413253336362−75069102
Other comprehensive income––00–000−10
Total comprehensive income––5433–62−75069102
Net margin6.3%6.8%11.5%7.9%11.1%12.0%−1.4%7.0%8.8%11.5%
Net margin without joint ventures and associates7.4%–––10.8%13.1%0.7%6.9%8.6%9.9%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2018 and Mar 2021 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 30 MayMar 2020Filed 6 JunMar 2021Mar 2022Filed 13 JunMar 2023Filed 24 MayMar 2024Filed 19 JulMar 2025Filed 13 JunMar 2026Filed 22 May
340348–470461536640786
340348–470461536640786
Share capital88–88899
Reserves331340–462452528631776
Belonging to outside owners of subsidiaries–0––0–00
130129–260253280311365
146145–196255332324353
91114–193164166189224
Total assets577608–8608801,0341,1531,362
369389–482469500598724
208219–377411534554638
Net debt115120–213245244269319
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2021, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2022Filed 13 JunMar 2023Filed 24 MayMar 2024Filed 19 JulMar 2025Filed 13 JunMar 2026Filed 22 May
4022508259
55276610283
−59−32−55−43−94
Receivables57−100−8833−13
Inventories−11328−10−51−66
Payables74044−377
Other working capital−110012−21
Tax paid−15−5−15−20−24
Capital spending273052123131
Free cash flow13−7−2−42−71
−27−30−52−123−131
−7−32314776
Dividends paid33334
Shares bought back00000
Shares issued0003848
Net change in cash6−392954
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021.

Per share

Consolidated, ₹ per share, years to March.SMS Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 6 JunMar 2021Mar 2022Filed 13 JunMar 2023Filed 24 MayMar 2024Filed 19 JulMar 2025Filed 13 JunMar 2026Filed 22 May
Earnings per share₹4.85––₹3.73₹7.39₹7.35−₹0.83₹5.89₹8.16₹11.15
Diluted earnings per share₹4.85––₹3.73₹7.39₹7.35–₹5.89₹8.16₹11.15
Dividend per share₹0.20₹0.25₹0.25₹0.25₹0.30₹0.30₹0.30₹0.40₹0.40₹0.40
Book value per share––₹40.16₹41.14–₹55.56₹54.40₹63.36₹72.15₹83.91
Dividend payout4.1%6.7%4.0%6.5%4.1%4.1%–6.8%5.2%3.7%
Shareholder yield–––––0.3%0.5%0.2%−1.9%−1.3%
Market cap at the year end (₹ crore)7256195312281,0527914931,5091,8013,511
Earnings per share is left blank for the year to Mar 2019: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Consolidated, years to March.SMS Pharmaceuticals PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 6 JunMar 2021Mar 2022Filed 13 JunMar 2023Filed 24 MayMar 2024Filed 19 JulMar 2025Filed 13 JunMar 2026Filed 22 May
Revenue growth8.4%−28.9%0.0%−11.4%36.7%−7.7%0.4%35.9%10.4%13.3%
Operating profit growth15.2%−9.2%−3.5%−11.3%51.5%−5.6%−52.3%114.0%19.2%23.2%
Net profit growth0.4%−22.6%68.3%−38.8%91.3%−0.5%––38.8%47.5%
Earnings per share growth0.4%–––98.1%−0.5%––38.5%36.6%
––15.7%9.5%–13.2%−1.5%10.0%11.7%14.3%
–––−6.2 pts––−14.7 pts11.5 pts1.7 pts2.7 pts
From the net margin–––−4.9 pts––−14.7 pts9.4 pts2.5 pts3.7 pts
From asset turnover–––−1.5 pts––0.0 pts1.8 pts−0.4 pts−0.2 pts
From borrowing–––0.1 pts––0.0 pts0.3 pts−0.4 pts−0.8 pts
Return on capital employed––15.1%12.1%–11.3%3.1%10.4%11.0%11.4%
Cash conversion–––––64.7%–100.6%118.2%58.1%
Interest cover3.64.76.04.78.94.41.03.65.65.7
Debt to equity––0.380.37–0.550.550.520.490.46
Receivable days––2043–341041229589
Inventory days––170191–333243201238260
Payable days––00–971231309589
Cash conversion cycle, days––190234–270224192237260
Working capital days––92111–172196167168178
Asset turnover––0.810.70–0.600.600.740.720.71
Assets per rupee of net worth––1.701.72–1.831.871.921.861.76
Sales per rupee of plant––1.661.50–1.201.271.631.471.67
Capital spending to depreciation–––––0.850.931.663.593.27
Plant being built, % of plant in use––6.5%15.3%–2.5%8.1%7.0%6.5%22.9%
No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2021, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.1%
Cash from operations against operating profit
34.6%
Measure10 years5 years3 years
Revenue growth, yearly rate3.9%9.5%19.3%
Profit growth, yearly rate9.6%10.3%–
Return on equity, average–9.5%12.0%
Return on capital employed, average–9.4%10.9%
Operating margin, average18.2%17.2%17.8%
Net margin, average8.2%7.6%9.1%
Asset turnover, average–0.670.72
Cash conversion cycle, days, average–237230
Interest cover, average4.84.15.0
Debt to equity, average–0.510.49

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations25419159
Cash from investing−363−306−131
Cash from financing11515476
Capital spending363306131
Dividends paid1594
Shares bought back000
Shares issued for cash868648
Borrowings raised27919788
Borrowings repaid19611634

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––––––866
Altman Z-scorePublished threshold 1.81––3.512.47–3.172.333.744.215.69
Beneish M-scorePublished threshold −1.78––––––−0.25−2.07−2.72−1.69
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––––0.025.4110.1413.80
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––––1.071.380.86
Receivables growth less revenue growthOur threshold 0 percentage points–––98.81––205.3323.38−24.33−7.09
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––10.56––−32.91−21.7818.8210.47
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.21––0.11−0.50−0.36−0.01
Assets under construction, years of additionsOur threshold 2 years of additions–––2.46––4.390.540.263.02
Effective tax ratePublished threshold 17.16 per cent19.3032.9714.2835.6033.090.9027.3925.5727.0124.55
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−20.88−58.612.285.533.89
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
9 Sep 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Letter of creditCARE A1Review, Re-affirm30
9 Sep 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Term LoanCARE AReview, Re-affirmStable349.07
9 Sep 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Cash CreditCARE AReview, Re-affirmStable141
9 Sep 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Packing Credit in Foreign CurrencyCARE AReview, Re-affirmStable80
9 Sep 2026CARE Ratings Limited (opens in a new tab)Fund-based - ST-Standby Line of CreditCARE A1Review, Re-affirm16
9 Sep 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Forward ContractCARE A1Review, Re-affirm4.83
9 Sep 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Bank GuaranteeCARE A1Review, Re-affirm2
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.